Antihypertensive Drugs Market Analysis & Key Business Strategies by Leading Industry Players

0
39

Human health is being affected by various factors which include rapid urbanization, demographic ageing and the globalization of unhealthy lifestyles. Hypertension is one of the keyhealth issuesthat are observed in both developed as well as developing countries. It is a silent, invisible killer that rarely causes symptoms and is one of the key risk factors forcoronary heart disease and ischemic as well as hemorrhagic stroke. Hypertension can also lead to various other problemssuch as renal impairment, visual impairment, heart failure and retinal hemorrhage. According to the World Health Organization (WHO), 7.5 million deaths globally are caused due to hypertension, and it accounts to 12.8% of the total deaths. Globally,in 2008 prevalence of hypertension was observed to be around 40% in adults aged 25. According to the National Health and Nutrition Evaluation Survey, ithas been noted that in United States from 2007 to 2010,81.5% of the population is aware of their hypertension condition, out of which 74% are being treated and only 52.5% are under control.

Report Overview @ https://www.transparencymarketresearch.com/antihypertensive-drugs-market.html

Theantihypertensive drugs market based on the therapy area is classified into diuretics (hydrochlorothiazide and indapamide), calcium channel blockers (nifedipine, felodipine and diltiazem), angiotensin receptor blockers or ARBs (losartan), angiotensin converting enzyme (ACE)inhibitors (captopril, lisinopril and perindopril), beta blockers vasodilators (atenolol and propranolol), alpha blockers (clonidine, guanabenz), and renin inhibitors.Diuretics being the first line of treatment for hypertension holds the major share of the market. All these drug classes (drugs) have shown to reduce cardiovascular morbidity and mortality. The drugs are administered either as a single or combined dose depending upon the stage of hypertension, whilethe choice of drugs depends upon the patients’ medical history and current conditions.

On the basis of the geography, the antihypertensive market can be segmented into North America, Europe, AsiaPacific, Latin America, and Middle East and Africa.The global antihypertensive market is dominated mainly by North America and Europe. According to the WHO, the prevalence of hypertension is highest in Africa and lowest in Americas. In Africa more than 40% of the adults suffer from hypertension and many of them remain undiagnosed due to the high cost of medications.The increased genericization by the local companies can be a challenge for the market. Similarly, in recent years, there has beena significant improvement in the management of hypertension contributing to a strong decline in the death rates in North America and Western Europe

Request Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=7718

The change in lifestyle, elevated stress level, and rise in prevalent population, early detection and penetration of combined dose would be the main factors to drive the growth of antihypertensive market. The patent expiry for major drugs such as Diovan (Novartis), Cozaar (Merck),Revatio (Pfizer), Exforge (Novartis), Atacand (AstraZeneca), Avapro (Sanofi Aventis), BIopress(Takeda) and Benicar (Daiichi Sankyo), along with low diagnostics rate and increased generic penetration would result in the antihypertensive market slowdown, but the novel antihypertensive drugs in the pipeline can recover the losses of patent expiration.

Some of the major key players in the global antihypertensive market includes Novartis AG, Pfizer Inc., Sanofi S.A, Johnson & Johnson Ltd., Daiichi – Sankyo, Merck & Co., AstraZeneca Plc.,Ranbaxy Laboratories Limited and Lupin Limited.